Advanced search
Publication Cover
Expert Opinion on Drug Safety Latest Articles
Submit an article Journal homepage
63
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Immune checkpoint inhibitor related myositis: an observational, retrospective, pharmacovigilance study

Hui Yanga Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China;b University of Chinese Academy of Sciences, Beijing, China;c Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, ChinaView further author information
,
Zhexin Dinga Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China;b University of Chinese Academy of Sciences, Beijing, ChinaView further author information
,
Zhuoling Anc Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, ChinaView further author information
,
Yong Zhaoa Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China;b University of Chinese Academy of Sciences, Beijing, China;d Faculty of Synthetic Biology, Shenzhen University of Advanced Technology, Shenzhen, China;e CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, ChinaCorrespondence[email protected]
View further author information
&
Hezhe Lua Key Laboratory of Organ Regeneration and Reconstruction, State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China;b University of Chinese Academy of Sciences, Beijing, ChinaCorrespondence[email protected]
View further author information
Received 11 Sep 2023, Accepted 26 Jan 2024, Published online: 24 Apr 2024

References

  • Saygin D, Ghosh N, Reid P. Immune checkpoint inhibitor–associated myositis. J Clin Rheumatol. 2022;28(7):367–373. doi: 10.1097/RHU.0000000000001874
  • Remash D, Prince DS, McKenzie C, et al. Immune checkpoint inhibitor-related hepatotoxicity: a review. World J Gastroenterol. 2021;27(32):5376–5391. doi: 10.3748/wjg.v27.i32.5376
  • Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus pla- cebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–1801. doi: 10.1056/NEJMoa1802357
  • Moreira A, Loquai C, Pföhler C, et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur J Cancer. 2019;106:12–23. doi: 10.1016/j.ejca.2018.09.033
  • Kobayashi M, Saiki M, Omori C, et al. Myositis induced by durvalumab in a patient with non-small cell lung cancer: a case report. Thorac Cancer. 2020;11:3614–3617. doi: 10.1111/1759-7714.13709
  • Rota E, Varese P, Agosti S, et al. Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: a life-threatening continuum of neuromuscular and cardiac toxicity. eNeurologicalSci. 2018;14:4–5. doi: 10.1016/j.ensci.2018.11.023
  • Tay SH, Wong AS, Jeyasekharan AD. A patient with pembrolizumab-induced fatal polymyositis. Eur J Cancer. 2018;91:180–182. doi: 10.1016/j.ejca.2017.12.019
  • Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427–436. doi: 10.1002/pds.1742
  • Yang H, Yu X, An Z. Cutaneous toxicity associated with enfortumab vedotin: a real-word study leveraging U.S. Food and drug administration adverse event reporting system. Front Oncol. 2022;11:801199. doi: 10.3389/fonc.2021.801199
  • Allenbach Y, Anquetil C, Manouchehri A, et al. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev. 2020;19:102586. doi: 10.1016/j.autrev.2020.102586
  • Hamada N, Maeda A, Takase-Minegishi K, et al. Incidence and distinct features of immune checkpoint inhibitor–related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis. Front Immunol. 2021;12:803410. doi: 10.3389/fimmu.2021.803410
  • Solimando AG, Crudele L, Leone P, et al. Immune checkpoint inhibitor-related myositis: from biology to bedside. Int J Mol Sci. 2020;21(9):3054. doi: 10.3390/ijms21093054
  • Touat M, Maisonobe T, Knauss S, et al. Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology. 2018;91(10):e985–e994. doi: 10.1212/WNL.0000000000006124
  • Anquetil C, Salem JE, Lebrun-Vignes B, et al. Immune checkpoint inhibitor–associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution. Circulation. 2018;138(7):743–745. doi: 10.1161/CIRCULATIONAHA.118.035898

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.